Table 3.
Subgroup analysis of immune cells and prognostic indices in EC patients.
| Group | Subgroup | Study number | Number of case | Pooled result, HR (95% CI) | PZ value | PH value | I 2 |
|---|---|---|---|---|---|---|---|
| CD8-OS | Intraepithelial | 3 | 630 | 0.320 (0.120-0.849) | 0.002 | 0.265 | 24.8% |
| Stromal | 1∗ | 110 | 0.064 (0.016-0.253) | 0.001 | 0.915 | 0.0% | |
| Whole# | 1 | 149 | 0.850 (0.070-10.560) | 0.899 | — | — | |
|
| |||||||
| CD8-PFS | Intraepithelial | 2 | 248 | 0.262 (0.111-0.621) | 0.002 | 0.612 | 0.0% |
| Stromal | 1 | 65 | 0.460 (0.040-5.220) | 0.532 | — | — | |
| Whole# | 1 | 149 | 0.790 (0.100-6.440) | 0.824 | — | — | |
|
| |||||||
| FoxP3+ T cell-OS | Intraepithelial | 1 | 163 | 1.000 (1.000-1.000) | 0.678 | — | — |
| Stromal | 2 | 189 | 1.264 (0.419-3.812) | 0.678 | 0.212 | 35.6% | |
|
| |||||||
| FoxP3+ T cell-RFS | Intraepithelial | 1 | 163 | 1.000 (1000-1.010) | 1.000 | — | — |
| Stromal | 1∗ | 110 | 1.103 (0.516-2.360) | 0.801 | 0.377 | 0.0% | |
|
| |||||||
| CD45RO+ T cell-OS | Intraepithelial | 1 | 368 | 0.490 (0.260-0.950) | 0.031 | — | — |
| Stromal | 1∗ | 110 | 0.280 (0.103-0.757) | 0.012 | 0.833 | 0.0% | |
|
| |||||||
| TAM-OS | CD68+ TAM | 2 | 262 | 3.219 (0.740-13.998) | 0.119 | 0.637 | 0.0% |
| CD163+ TAM | 1 | 163 | 1.400 (0.410-4.860) | 0.586 | — | — | |
| FIGO stage I-III | 1 | 76 | 1.810 (0.109-29.996) | 0.679 | — | — | |
| FIGO stage I-IV | 2 | 349 | 2.008 (0.735-5.487) | 0.174 | 0.336 | 0.0% | |
|
| |||||||
| TAM-RFS-c/d | Intraepithelial | 3 | 293 | 3.582 (0.889-14.264)/1.397 (0.260-7.508) | 0.070/0.696 | 0.210/0.052 | 36%/66.2% |
| Stromal | 1 | 186 | 4.200 (1.900–99.800) | 0.156 | — | — | |
| CD68+ TAM | 3 | 316 | 2.627 (0.858-8.049)/1.104 (0.293-4.156) | 0.091/0.883 | 0.343/0.159 | 6.5%/45.7% | |
| CD163+ TAM | 1 | 163 | 8.310 (1.030-67.300) | 0.035 | — | — | |
|
| |||||||
| TAM-RFS-e/f | Intraepithelial | 2 | 223 | 2.836 (0.431-18.676) | 0.278 | 0.127 | 57.0% |
| Stromal | 2 | 256 | 2.277 (0.665-7.792)/2.056 (0.651-6.494) | 0.179/0.219 | 0.439/0.385 | 0.0% | |
| CD68+ TAM | 3 | 316 | 1.766 (0.679-4.590)/1.689 (0.676-4.222) | 0.243/0.262 | 0.603/0.588 | 0.0% | |
| CD163+ TAM | 1 | 163 | 8.310 (1.030-67.300) | 0.035 | — | — | |
PZ: p value of the Z-test; PH: p value of the heterogeneity test. ∗One study included two groups. #Study calculated immune cells in the whole tumour tissue.